NDA 022065 · R-Pharm US LLC
Ixempra Kit
Ixabepilone · Intravenous
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jan 11, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Oct 16, 2007
Approved uses
3
Original approval plus efficacy supplements
Registered trials
118
9 Phase 3, 0 recruiting
FAERS reports
1,051
857 serious, 242 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: TOXICITY IN PATIENTS WITH HEPATIC IMPAIRMENT IXEMPRA in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN due to increased risk of toxicity and neutropenia-related death [see Contraindications ( 4 ) and Warnings and Precautions ( 5.3 )]. WARNING: TOXICITY IN PATIENTS WITH HEPATIC IMPAIRMENT See full prescribing information for complete boxed warning. IXEMPRA ® in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN due to increased risk of toxicity and neutropenia-related death. ( 4 , 5.3 )
What it is approved for
From the label in effect Dec 4, 2025.
IXEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting [see Clinical Studies ( 14 )]. IXEMPRA is indicated as a single agent for the treatment of patients with metastatic or locally advanced breast cancer whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine [see Clinical Studies ( 14 )]. IXEMPRA is a microtubule inhibitor indicated for treatment: In combination with capecitabine for patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. ( 1 ). As a single agent for patients with metastatic or locally advanced breast cancer after failure of an anthracycline, a taxane, and capecitabine. ( 1 ).
Mechanism: Ixabepilone is a semi-synthetic analog of epothilone B. Ixabepilone binds directly to β-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of αβ-II and αβ-III microtubules. Ixabepilone possesses low in vitro susceptibility to multiple tumor resistance mechanisms including efflux transporters, such as MRP-1 and P-glycoprotein (P-gp). Ixabepilone blocks cells in the mitotic phase of the cell division cycle, leading to cell death.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 18, 2011 Supplement 6 · Efficacy · priority review LabelPediatric Written RequestPediatric Amendment 1
- Oct 2, 2009 Supplement 2 · Efficacy LabelLetter
- Oct 16, 2007 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLabelLetter
2 products under this application
- IXEMPRA KIT · IXABEPILONE 45MG/VIAL · INJECTABLE, INTRAVENOUS · Prescription
- IXEMPRA KIT · IXABEPILONE 15MG/VIAL · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ixabepilone" as an intervention, any sponsor and status, largest first.
- Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerPivotal-lookingCompleted
R-PharmIndustry
NCT00082433 · 1,221 participants · Start Nov 2003 · Primary completion Mar 2008
Drug: Ixabepilone + Capecitabine; Capecitabine · For: Cancer; Breast Cancer
Sites: Tucson, Arizona; Beverly Hills, California; Corona, California · 186 sites in all
- The BEACON Study (Breast Cancer Outcomes With NKTR-102)Pivotal-lookingCompleted
Nektar TherapeuticsIndustry
NCT01492101 · 852 participants · Start Dec 2011 · Primary completion Apr 2016
Drug: NKTR-102; Treatment of Physician's Choice (TPC) · For: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Sites: Flagstaff, Arizona; Burbank, California; Los Angeles, California · 153 sites in all
- Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00785291 · 799 participants · Start Oct 13, 2008 · Primary completion Dec 31, 2013
Drug: Bevacizumab; Ixabepilone and 2 more · For: Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative and 6 more
Sites: Scottsdale, Arizona; Fort Smith, Arkansas; Jonesboro, Arkansas · 704 sites in all
- Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast CancerPivotal-lookingCompleted
UNICANCERAcademic, hospital or other
NCT00630032 · 762 participants · Start Sep 2007 · Primary completion Jun 2017
Drug: cyclophosphamide; Docetaxel and 3 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Denver, Colorado; Jacksonville, Florida · 86 sites in all
- Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerPivotal-lookingCompleted
R-PharmIndustry
NCT00080301 · 752 participants · Start Sep 2003 · Primary completion Nov 2006
Drug: Ixabepilone + Capecitabine; Capecitabine · For: Breast Cancer; Metastases
Sites: Little Rock, Arkansas; San Francisco, California; Vallejo, California · 127 sites in all
- A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast CancerPivotal-lookingCompleted
SCRI Development Innovations, LLCAcademic, hospital or other
NCT00789581 · 614 participants · Start Dec 2008 · Primary completion Dec 2015
Drug: Doxorubicin; Cyclophosphamide and 2 more · For: Breast Cancer
Sites: Anniston, Alabama; Huntsville, Alabama; Mobile, Alabama · 70 sites in all
- A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial CancerPivotal-lookingTerminated
R-PharmIndustry
NCT00883116 · 551 participants · Start Aug 2009 · Primary completion Jun 2012
Drug: Ixabepilone; Doxorubicin and 1 more · For: Endometrial Cancer
Sites: Mobile, Alabama; Englewood, Colorado; New Haven, Connecticut · 93 sites in all
- Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast CancerPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00455533 · 384 participants · Start Oct 2007 · Primary completion Dec 2009
Drug: Ixabepilone; Paclitaxel and 2 more · For: Breast Cancer
Sites: Palm Springs, California; Coral Spring, Florida; Davie, Florida · 49 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death106
- vomiting94
- nausea93
- anaemia91
- fatigue89
- diarrhoea76
- malignant neoplasm progression70
- neutropenia70
- white blood cell count decreased69
- neutrophil count decreased67
- dyspnoea60
- dehydration57
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 21 |
| 2006 | 27 |
| 2007 | 23 |
| 2008 | 95 |
| 2009 | 79 |
| 2010 | 85 |
| 2011 | 57 |
| 2012 | 139 |
| 2013 | 84 |
| 2014 | 81 |
| 2015 | 70 |
| 2016 | 117 |
| 2017 | 52 |
| 2018 | 30 |
| 2019 | 10 |
| 2020 | 7 |
| 2021 | 15 |
| 2022 | 23 |
| 2023 | 4 |
| 2024 | 9 |
| 2025 | 9 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.
Haiderali A, Huang M, Pan W, et al. · Future Oncol 2024 · Systematic Review, Network Meta-Analysis
- A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
Aghajanian C, Filiaci V, Dizon DS, et al. · Gynecol Oncol 2018 · Clinical Trial, Phase II, Multicenter Study
- Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer.
Li L, Li J, Yang K, et al. · Future Oncol 2010 · Systematic Review
- Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
Sachdev JC, Jahanzeb M · Clin Breast Cancer 2016 · Research Support, Non-U.S. Gov't, Systematic Review
- A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).
Rashkin SR, Chua KC, Ho C, et al. · Clin Pharmacol Ther 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.
Qin Z, Li X, Zhang J, et al. · Medicine (Baltimore) 2016 · Meta-Analysis, Systematic Review
Sponsor: R-Pharm US LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.